Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Arcutis Biotherapeutics Inc shares valued at $72,133 were purchased by Masaru Matsuda on Nov 19 ’25. At $28.29 per share, Masaru Matsuda acquired 2,550 shares.
Also, Krishnamohan Neha sold 40,504 shares, netting a total of over 939,494 in proceeds. Following the sale of shares at $23.20 each, the insider now holds 22,123 shares.
Before that, Neha Krishnamohan had added 40,504 shares to its account. In a trade valued at $939,273, the Director bought Arcutis Biotherapeutics Inc shares for $23.19 each.
As published in their initiating research note from Goldman on July 25, 2025, Arcutis Biotherapeutics Inc [ARQT] has been a Neutral and the price target has been revised to $18. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in late December. As of August 28, 2024, Jefferies has initiated its “Buy” rating for ARQT. Earlier on January 03, 2024, Mizuho upgraded its rating. Their new recommendation was “a Buy” for ARQT stock which previously was a “a Neutral”.
Analyzing ARQT Stock Performance
On last trading session, Arcutis Biotherapeutics Inc [NASDAQ: ARQT] rose 2.24% to $27.89. The stock’s lowest price that day was $27.0, but it reached a high of $28.96 in the same session. During the last five days, there has been a surge of approximately 18.93%. Over the course of the year, Arcutis Biotherapeutics Inc shares have jumped approximately 201.19%. Shares of the company reached a 52-week high of $28.96 on 11/19/25 and a 52-week low of $11.13 on 02/11/25.
Support And Resistance Levels for Arcutis Biotherapeutics Inc (ARQT)
According to the 24-hour chart, there is a support level at 26.94, which, if violated, would cause prices to drop to 25.99. In the upper region, resistance lies at 28.90. The next price resistance is at 29.91. RSI (Relative Strength Index) is 71.00 on the 14-day chart, showing overbought technical sentiment.
Is Arcutis Biotherapeutics Inc subject to short interest?
Stocks of Arcutis Biotherapeutics Inc saw a sharp steep in short interest on 2025-10-31 dropping by -0.97 million shares to 13.48 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 14.45 million shares. A decline of -7.22% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.34 of the overall float, the days-to-cover ratio (short ratio) decline to 5.34.
Which companies own the most shares of Arcutis Biotherapeutics Inc (ARQT)?
In terms of Arcutis Biotherapeutics Inc share price expectations, FactSet research, analysts set an average price target of 30 in the next 12 months, up nearly 9.97% from the previous closing price of $27.28. Analysts anticipate Arcutis Biotherapeutics Inc stock to reach 32 by 2025, with the lowest price target being 29. In spite of this, 3 analysts ranked Arcutis Biotherapeutics Inc stock as Buy at the end of 2025. On October 26, 2023, Mizuho assigned a price target of “a Neutral” to the stock and downgraded coverage with a $4.
